COMMUNIQUÉS West-GlobeNewswire

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
24/09/2026
Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the [...]
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
24/09/2026
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3- [...]
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
24/09/2026
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to [...]
Sofwave Receives NMPA Approval in Mainland China
24/09/2026
NMPA approval supported by a 200-subject, randomized, controlled study in China demonstrating statistically significant improvement in mid-to-lower facial wrinkles and a favorable safety profile China represents a [...]
Immuneering to Present at the ESMO Congress 2026
24/09/2026
- Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients - NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation ( [...]
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
24/09/2026
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel ARLINGTON, Mass., Sept. 24, 2026 ( [...]
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
24/09/2026
BERKELEY, CA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies today announced that the Company has received a positive decision [...]
Kraig Biocraft Laboratories Reaches Major Scientific Milestone with Completion of Functional and Living Atlas Gene Library
24/09/2026
ANN ARBOR, Mich., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a major [...]
Coave Therapeutics to Present New Data on Wet AMD Gene Therapy Program at 26th Euretina Congress as it Advances towards the Clinic
24/09/2026
Dr. Nora Dimon, VP of Clinical Development, to present preclinical findings on the Company’s lead retinal program, CoTx-101, including non-human primate data Rodolphe Clerval, CEO, to deliver a corporate presentation at [...]
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
24/09/2026
TORONTO and HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting [...]
What CX Leaders Should Understand About Customer Support Outsourcing
24/09/2026
Transcom supports more than 300 clients globally, including disruptive e-commerce players and category-redefining fintechs, across 29 countries. Transcom's autopilot conversational AI bots resolve high-volume contacts [...]
Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics
24/09/2026
Collaboration leverages Atavistik Bio’s proprietary AMPS TM platform to identify and advance novel allosteric small molecules against multiple targets for cardiometabolic diseases Atavistik Bio to receive $70 million [...]
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
24/09/2026
FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical need FSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the [...]
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
24/09/2026
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December CLN-049 (FLT3 TCE) updated data from the [...]
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
24/09/2026
Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company’s website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE [...]
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
24/09/2026
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell [...]
PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment
24/09/2026
SHIELD Phase 2 Study: first payment made under the clinical trial agreement with Mount Sinai and study drug ordered; the randomized, double-blind, placebo-controlled study, registered as NCT07597902, plans to enroll [...]
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
24/09/2026
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the [...]
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
24/09/2026
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct Sustained clinical [...]

Pages